Shares of dialysis providers and kidney care stocks are trading lower after Novo Nordisk stopped its semaglutide kidney outcomes trial early based on early signs of efficacy.
Portfolio Pulse from Bill Haddad
Shares of dialysis providers and kidney care stocks are trading lower after Novo Nordisk stopped its semaglutide kidney outcomes trial early based on early signs of efficacy. Companies potentially affected include BAX, DVA, FMS, and ISRG.
October 11, 2023 | 3:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Baxter International's stock may be negatively impacted by Novo Nordisk's early stop of semaglutide kidney trial.
Baxter International, as a provider of dialysis and kidney care services, may see a decrease in demand if Novo Nordisk's semaglutide proves effective in treating kidney conditions.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
DaVita Inc.'s stock may be negatively impacted by Novo Nordisk's early stop of semaglutide kidney trial.
DaVita Inc., as a provider of dialysis and kidney care services, may see a decrease in demand if Novo Nordisk's semaglutide proves effective in treating kidney conditions.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
Fresenius Medical Care's stock may be negatively impacted by Novo Nordisk's early stop of semaglutide kidney trial.
Fresenius Medical Care, as a provider of dialysis and kidney care services, may see a decrease in demand if Novo Nordisk's semaglutide proves effective in treating kidney conditions.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
Intuitive Surgical's stock may be negatively impacted by Novo Nordisk's early stop of semaglutide kidney trial.
Intuitive Surgical, as a provider of dialysis and kidney care services, may see a decrease in demand if Novo Nordisk's semaglutide proves effective in treating kidney conditions.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75